University Clinical Center Kragujevac
Kragujevac, Serbia
15 recruiting
Showing 1–20 of 32 trials
Recruiting
Phase 3
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Lung CancerSCLCSmall Cell Lung Cancer+5 more
SystImmune Inc.550 enrolledNCT07625644
Recruiting
Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Contineum Therapeutics324 enrolled53 locationsNCT07284459
Recruiting
Phase 2Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled148 locationsNCT06159673
Recruiting
Phase 3
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Carcinoma, Squamous Cell
Johnson & Johnson Enterprise Innovation Inc.500 enrolled193 locationsNCT04892173
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Alzheimer DiseasePsychotic Disorders
Intra-Cellular Therapies, Inc.370 enrolled65 locationsNCT06540833
Recruiting
Phase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.570 enrolled60 locationsNCT06701903
Recruiting
Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.705 enrolled69 locationsNCT06480383
Recruiting
Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Intra-Cellular Therapies, Inc.470 enrolled69 locationsNCT05850689
Recruiting
Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company406 enrolled292 locationsNCT06585787
Recruiting
Phase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.180 enrolled59 locationsNCT07029581
Recruiting
Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Chronic Migraine in Children
H. Lundbeck A/S285 enrolled84 locationsNCT04965675
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company410 enrolled129 locationsNCT05511363
Recruiting
Phase 3
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Dravet Syndrome
Longboard Pharmaceuticals104 enrolled102 locationsNCT06660394
Recruiting
Phase 1
A Study in Leukemia Patients With Karonudib
Leukemia
Thomas Helleday Foundation50 enrolled6 locationsNCT04077307
Recruiting
Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer
Locally Advanced Cervical CancerVitamin D Concentration
University of Kragujevac100 enrolledNCT07743918
Recruiting
Phase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company1,000 enrolled429 locationsNCT05980949
Recruiting
Phase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Migraine
H. Lundbeck A/S600 enrolled70 locationsNCT05164172
Recruiting
Phase 3
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals320 enrolled114 locationsNCT06719141
Recruiting
Phase 2
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
COPD Acute Exacerbation
Connect Biopharm LLC160 enrolled53 locationsNCT06940154
Recruiting
Phase 2
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
Asthma Acute
Connect Biopharm LLC160 enrolled59 locationsNCT06940141